Takeda's ENTYVIO Trial Achieves Primary Endpoint in Ulcerative Colitis, Demonstrating Reduced Complication Risk

New data from Takeda's Phase 4 VERDICT clinical trial show that treating adults with intravenous ENTYVIO (vedolizumab) to achieve corticosteroid-free disease clearance significantly reduced the risk of ulcerative colitis-related complications by nearly 70%. This marks the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in moderate to severe ulcerative colitis.